# Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial

> **NCT04394377** · PHASE4 · COMPLETED · sponsor: **Brazilian Clinical Research Institute** · enrollment: 615 (actual)

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed
- **DRUG:** Group 2: control group with enoxaparin 40mg/d

## Key facts

- **NCT ID:** NCT04394377
- **Lead sponsor:** Brazilian Clinical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-21
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-05-30
- **Target enrollment:** 615 (ACTUAL)
- **Last updated:** 2021-06-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04394377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04394377, "Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04394377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*